Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is
the fourth most common malignancy and the second leading cause of tumor-related death, …

Background There is no standard of care for adjuvant therapy for patients with hepatocellular
carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus …

Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular
carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered …

Background and aims Golgi protein 73 (GP73) as a potential serum marker for hepatocellular
carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its …

Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal.
Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies. …

Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …

Liquid biopsies, based on cell free DNA (cfDNA) and proteins, have shown the potential to
detect early stage cancers of diverse tissue types. However, most of these studies were …

Purpose: Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of doxorubicin contained
within a heat-sensitive liposome. When heated to ≥40C, LTLD locally releases a high …

Aflatoxin exposure is a crucial factor in promoting the development of primary hepatocellular
carcinoma (HCC) in individuals infected with the hepatitis virus. However, the molecular …

Background & Aims Dietary exposure to aflatoxin is an important risk factor for hepatocellular
carcinoma (HCC). However, little is known about the genomic features and mutations of …